Table 1 Demographics and Baseline Variables

Age, years (IQR)

40.0 (33.5 – 47.5)

39.5 (30.5 – 55.8)

40.0 (34.5 – 45.5)

Sex (n)

 Male

51% (24)

50% (8)

52% (16)

 Female

49% (23)

50% (8)

48% (15)

Race (n)

 Black

87% (41)

75% (12)

94% (29)

 White

6% (3)

19% (3)

0% (0)

 Coloured

6% (3)

6% (1)

6% (2)

Wealth Quintile (n)

 1

21% (7)

20% (2)

22% (5)

 2

15% (5)

20% (2)

13% (3)

 3

21% (7)

20% (2)

22% (5)

 4

24% (8)

20% (2)

26% (6)

 5

18% (6)

20% (2)

17% (4)

ECOG PS (n)

 0 or 1

45% (21)

50% (8)

42% (13)

 > 2

55% (26)

50% (8)

58% (18)

B Symptoms (n)

 Present

98% (46)

94% (15)

100% (31)

 Absent

2% (1)

6% (1)

0% (0)

Stage (n)

 1 or 2

13% (6)

25% (4)

6% (2)

 3 or 4

87% (41)

75% (12)

94% (29)

Bone Marrow (n)

 Involved

47% (22)

12% (2)

65% (20)

 Un-involved

53% (25)

88% (14)

35% (11)

IPS (n)

 < 4

38% (18)

62% (10)

26% (8)

 ≥ 4

62% (29)

38% (6)

74% (23)

CD4, cells/μL (IQR)

–

–

103.0 (59.0–290.0)

HIV Viral Load, copies/mL (n)

 < 200

–

–

81% (25)

 ≥ 200

19% (6)

ART (n)

 Yes

–

–

90% (28)

 No

10% (3)

WBC,10⁹/L (IQR)

4.6 (3.1–11.3)

11.6 (5.2–14.9)

3.8 (2.6–8.7)

Hemoglobin, g/dL (IQR)

8.9 (7.2–10.9)

11.2 (9.5–13.0)

7.9 (6.4–9.2)

Platelet, 10⁹/L (IQR)

304.0 (96.0–511.5)

428.5 (300.8–516.8)

197.0 (40.5–452.0)

ALC, 10⁹/L (IQR)

0.9 (0.4–1.5)

1.5 (1.1–2.2)

0.5 (0.3–1.1)

Albumin, g/L (IQR)

31.0 (24.0–35.5)

38.0 (33.8–42.0)

26.0 (23.0–32.0)

TB Treatment (n)

 No

83% (39)

94% (15)

77% (24)

 Yes

17% (8)

6% (1)

23% (7)

EBER Available (n)

 Yes

60% (28)

56% (9)

61% (19)

 No

40% (19)

44% (7)

39% (12)

EBER Evaluable (n)

 Positive

68% (19)

33% (3)

84% (16)

 Negative

32% (9)

67% (6)

16% (3)